ABSTRACT
In situ vaccines (ISVs) utilize the localized delivery of chemotherapeutic agents or radiotherapy to stimulate the release of endogenous antigens from tumors, thereby eliciting systemic and persistent immune activation. Recently, a bioinspired ISV strategy has attracted tremendous attention due to its features such as an immune adjuvant effect and genetic plasticity. M13 bacteriophages are natural nanomaterials with intrinsic immunogenicity, genetic flexibility, and cost-effectiveness for large-scale production, demonstrating the potential for application in cancer vaccines. In this study, we propose an ISV based on the engineered M13 bacteriophage targeting CD40 (M13CD40) for dendritic cell (DC)-targeted immune stimulation, named H-GM-M13CD40. We induce immunogenic cell death and release tumor antigens through local delivery of (S)-10-hydroxycamptothecin (HCPT), followed by intratumoral injection of granulocyte-macrophage colony stimulating factor (GM-CSF) and M13CD40 to enhance DC recruitment and activation. We demonstrate that this ISV strategy can result in significant accumulation and activation of DCs at the tumor site, reversing the immunosuppressive tumor microenvironment. In addition, H-GM-M13CD40 can synergize with the PD-1 blockade and induce abscopal effects in cold tumor models. Overall, our study verifies the immunogenicity of the engineered M13CD40 bacteriophage and provides a proof of concept that the engineered M13CD40 phage can function as an adjuvant for ISVs.
Subject(s)
Bacteriophage M13 , Cancer Vaccines , Dendritic Cells , Tumor Microenvironment , Cancer Vaccines/immunology , Tumor Microenvironment/immunology , Tumor Microenvironment/drug effects , Animals , Bacteriophage M13/immunology , Bacteriophage M13/chemistry , Mice , Dendritic Cells/immunology , CD40 Antigens/immunology , CD40 Antigens/metabolism , Mice, Inbred C57BL , Female , Cell Line, Tumor , Granulocyte-Macrophage Colony-Stimulating Factor , Antigens, Neoplasm/immunology , HumansABSTRACT
The 2018 Nobel Prize in Chemistry recognized in vitro evolution, including the development by George Smith and Gregory Winter of phage display, a technology for engineering the functional capabilities of antibodies into viruses. Such bacteriophages solve inherent problems with antibodies, including their high cost, thermal lability, and propensity to aggregate. While phage display accelerated the discovery of peptide and protein motifs for recognition and binding to proteins in a variety of applications, the development of biosensors using intact phage particles was largely unexplored in the early 2000s. Virus particles, 16.5 MDa in size and assembled from thousands of proteins, could not simply be substituted for antibodies in any existing biosensor architectures.Incorporating viruses into biosensors required us to answer several questions: What process will allow the incorporation of viruses into a functional bioaffinity layer? How can the binding of a protein disease marker to a virus particle be electrically transduced to produce a signal? Will the variable salt concentration of a bodily fluid interfere with electrical transduction? A completely new biosensor architecture and a new scheme for electrical transduction of the binding of molecules to viruses were required.This Account describes the highlights of a research program launched in 2006 that answered these questions. These efforts culminated in 2018 in the invention of a biosensor specifically designed to interface with virus particles: the Virus BioResistor (VBR). The VBR is a resistor consisting of a conductive polymer matrix in which M13 virus particles are entrained. The electrical impedance of this resistor, measured across 4 orders of magnitude in frequency, simultaneously measures the concentration of a target protein and the ionic conductivity of the medium in which the resistor is immersed. Large signal amplitudes coupled with the inherent simplicity of the VBR sensor design result in high signal-to-noise ratio (S/N > 100) and excellent sensor-to-sensor reproducibility. Using this new device, we have measured the urinary bladder cancer biomarker nucleic acid deglycase (DJ-1) in urine samples. This optimized VBR is characterized by extremely low sensor-to-sensor coefficients of variation in the range of 3-7% across the DJ-1 binding curve down to a limit of quantitation of 30 pM, encompassing 4 orders of magnitude in concentration.
Subject(s)
Bacteriophage M13/isolation & purification , Biosensing Techniques/methods , Antibodies/immunology , Bacteriophage M13/chemistry , Bacteriophage M13/immunology , Bacteriophage M13/metabolism , Biomarkers, Tumor/urine , Biosensing Techniques/instrumentation , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Electrodes , Humans , Limit of Detection , Nanowires/chemistry , Neoplasms/diagnosis , Peptide Library , Polymers/chemistry , Protein Deglycase DJ-1/urine , Quartz Crystal Microbalance Techniques , Reproducibility of Results , Signal-To-Noise RatioABSTRACT
Bacteriophage (phage) have attractive advantages as delivery systems compared with mammalian viruses, but have been considered poor vectors because they lack evolved strategies to confront and overcome mammalian cell barriers to infective agents. We reasoned that improved efficacy of delivery might be achieved through structural modification of the viral capsid to avoid pre- and postinternalization barriers to mammalian cell transduction. We generated multifunctional hybrid adeno-associated virus/phage (AAVP) particles to enable simultaneous display of targeting ligands on the phage's minor pIII proteins and also degradation-resistance motifs on the very numerous pVIII coat proteins. This genetic strategy of directed evolution bestows a next-generation of AAVP particles that feature resistance to fibrinogen adsorption or neutralizing antibodies and ability to escape endolysosomal degradation. This results in superior gene transfer efficacy in vitro and also in preclinical mouse models of rodent and human solid tumors. Thus, the unique functions of our next-generation AAVP particles enable improved targeted gene delivery to tumor cells.
Subject(s)
Bacteriophage M13/genetics , Dependovirus/genetics , Genetic Therapy/methods , Genetic Vectors/genetics , Neoplasms/therapy , Animals , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Bacteriophage M13/immunology , Capsid Proteins/genetics , Capsid Proteins/immunology , Cell Line, Tumor , Dependovirus/immunology , Endosomes/immunology , Endosomes/virology , Genetic Vectors/administration & dosage , Genetic Vectors/immunology , Humans , Lysosomes/immunology , Lysosomes/virology , Mice , Neoplasms/genetics , Oligopeptides/genetics , Oligopeptides/immunology , Proof of Concept Study , Rats , Transduction, Genetic/methods , Virus Internalization , Xenograft Model Antitumor AssaysABSTRACT
Sepsis is a systemic inflammatory response ensuing from presence and persistence of microorganisms in the bloodstream. The possibility to identify them at low concentrations may improve the problem of human health and therapeutic outcomes. So, sensitive and rapid diagnostic systems are essential to evaluate bacterial infections during the time, also reducing the cost. In this study, from random M13 phage display libraries, we selected phage clones that specifically bind surface of Staphyloccocus aureus, Pseudomonas aeruginosa and Escherichia coli. Then, commercial magnetic beads were functionalized with phage clones through covalent bond and used as capture and concentrating of pathogens from blood. We found that phage-magnetic beads complex represents a network which enables a cheap, high sensitive and specific detection of the bacteria involved in sepsis by micro-Raman spectroscopy. The enter process required 6â¯h and has the limit of detection of 10 Colony Forming Units on 7â¯ml of blood (CFU/7â¯ml).
Subject(s)
Bacteria , Bacteriophage M13/chemistry , Immunomagnetic Separation , Peptide Library , Sepsis , Bacteria/classification , Bacteria/growth & development , Bacteria/isolation & purification , Bacteriophage M13/immunology , Humans , Limit of Detection , Sepsis/blood , Sepsis/microbiology , Spectrum Analysis, RamanABSTRACT
Antibodies are essential for characterizing various analytes. "Molecular-breeding" approaches enable rapid generation of antibody mutants with desirable antigen-binding abilities. Typically, prototype antibodies are converted to single-chain Fv fragments (scFvs), and random mutations are genetically introduced to construct molecular libraries with a vast diversity. Improved species therein are then isolated via phage display genotype-phenotype-connecting systems to separate them from a large excess of nonspecific scFvs. During these experiments, counting of phage particles is routinely performed. However, current methods depend on the time-consuming overnight cultivation of phage-infected bacteria on agar plates to estimate phage numbers as plaque-forming units (pfu) or colony-forming units, the results of which fluctuate considerably. Immunochemical systems capturing phage particles should be a more convenient and robust alternative. We therefore generated monoclonal antibodies against M13 filamentous phage, which is commonly used for phage display, by employing hybridoma technology. Combinatorial use of two such antibodies (Ab-M13#53 and #71; both specific to the major coat protein pVIII) enabled development of a sandwich enzyme-linked immunosorbent assay (ELISA) that could measure ca. 107-1010 phage pfu/mL. To construct a more convenient system, Ab-M13#71 was converted to the scFv form and further fused with an alkaline phosphatase variant. Using this fusion protein, the sandwich ELISA enabled rapid (within 90 min) and reliable phage counting without reducing the sensitivity, and the results were reasonably consistent with those of infection-based methods. The present anti-phage antibodies and scFvs might also enable visualization of individual phage particles by combining them with sensitive fluorescent staining.
Subject(s)
Antibodies, Monoclonal/genetics , Bacteriophage M13/immunology , DNA Shuffling/methods , Single-Chain Antibodies/genetics , Antibodies, Monoclonal/immunology , Enzyme-Linked Immunosorbent Assay/methods , Hybridomas , Reproducibility of Results , Single-Chain Antibodies/immunologyABSTRACT
Recombinant filamentous fd bacteriophages (rfd) expressing antigenic peptides were shown to induce cell-mediated immune responses in the absence of added adjuvant, being a promising delivery system for vaccination. Here, we tested the capacity of rfd phages to protect against infection with the human protozoan Trypanosoma cruzi, the etiologic agent of Chagas Disease. For this, C57BL/6 (B6) and Tlr9-/- mice were vaccinated with rfd phages expressing the OVA257-264 peptide or the T. cruzi-immunodominant peptides PA8 and TSKB20 and challenged with either the T. cruzi Y-OVA or Y-strain, respectively. We found that vaccination with rfd phages induces anti-PA8 and anti-TSKB20 IgG production, expansion of Ag-specific IFN-γ, TNF-α, and Granzyme B-producing CD8+ T cells, as well as in vivo Ag-specific cytotoxic responses. Moreover, the fd-TSKB20 vaccine was able to protect against mortality induced by a high-dose inoculum of the parasite. Although vaccination with rfd phages successfully reduced both parasitemia and parasite load in the myocardium of WT B6 mice, Tlr9-/- animals were not protected against infection. Thus, our data extend previous studies, demonstrating that rfd phages induce Ag-specific IgG and CD8+ T cell-mediated responses and confer protection against an important human parasite infection, through a TLR9-dependent mechanism.
Subject(s)
Bacteriophage M13 , Chagas Disease , Gene Expression Regulation , Protozoan Vaccines , Toll-Like Receptor 9 , Trypanosoma cruzi , Vaccination , Animals , Bacteriophage M13/genetics , Bacteriophage M13/immunology , Chagas Disease/genetics , Chagas Disease/immunology , Chagas Disease/prevention & control , Gene Expression Regulation/drug effects , Gene Expression Regulation/immunology , Mice , Mice, Knockout , Protozoan Vaccines/genetics , Protozoan Vaccines/immunology , Protozoan Vaccines/pharmacology , Toll-Like Receptor 9/genetics , Toll-Like Receptor 9/immunology , Trypanosoma cruzi/genetics , Trypanosoma cruzi/immunologyABSTRACT
We describe a method for the rapid selection of functional antibodies. The method depends on the cocultivation of Escherichia coli that produce phage with target eukaryotic cells in very small volumes. The antibodies on phage induce selectable phenotypes in the target cells, and the nature of the antibody is determined by gene sequencing of the phage genome. To select functional antibodies from the diverse antibody repertoire, we devised a selection platform that contains millions of picoliter-sized droplet ecosystems. In each miniecosystem, the bacteria produce phage displaying unique members of the antibody repertoire. These phage interact only with eukaryotic cells in the same miniecosystem, making phage available directly for activity-based antibody selection in biological systems.
Subject(s)
Bacteriophage M13 , Escherichia coli , Membrane Glycoproteins/antagonists & inhibitors , Receptor, trkB/antagonists & inhibitors , Single-Chain Antibodies , Animals , Bacteriophage M13/genetics , Bacteriophage M13/immunology , CHO Cells , Coculture Techniques , Cricetulus , Escherichia coli/genetics , Escherichia coli/immunology , Humans , Membrane Glycoproteins/immunology , Receptor, trkB/immunology , Single-Chain Antibodies/genetics , Single-Chain Antibodies/immunologyABSTRACT
Bacteria and archaea generate adaptive immunity against phages and plasmids by integrating foreign DNA of specific 30-40-base-pair lengths into clustered regularly interspaced short palindromic repeat (CRISPR) loci as spacer segments. The universally conserved Cas1-Cas2 integrase complex catalyses spacer acquisition using a direct nucleophilic integration mechanism similar to retroviral integrases and transposases. How the Cas1-Cas2 complex selects foreign DNA substrates for integration remains unknown. Here we present X-ray crystal structures of the Escherichia coli Cas1-Cas2 complex bound to cognate 33-nucleotide protospacer DNA substrates. The protein complex creates a curved binding surface spanning the length of the DNA and splays the ends of the protospacer to allow each terminal nucleophilic 3'-OH to enter a channel leading into the Cas1 active sites. Phosphodiester backbone interactions between the protospacer and the proteins explain the sequence-nonspecific substrate selection observed in vivo. Our results uncover the structural basis for foreign DNA capture and the mechanism by which Cas1-Cas2 functions as a molecular ruler to dictate the sequence architecture of CRISPR loci.
Subject(s)
Adaptive Immunity , CRISPR-Associated Proteins/metabolism , Clustered Regularly Interspaced Short Palindromic Repeats/genetics , DNA, Viral/genetics , DNA, Viral/immunology , Virus Integration , Bacteriophage M13/genetics , Bacteriophage M13/immunology , Base Sequence , CRISPR-Associated Proteins/chemistry , Catalytic Domain , Crystallography, X-Ray , DNA, Viral/chemistry , DNA, Viral/metabolism , Escherichia coli/enzymology , Escherichia coli/genetics , Escherichia coli/immunology , Escherichia coli/virology , Integrases/chemistry , Integrases/metabolism , Models, Molecular , Virus Integration/genetics , Virus Integration/immunologyABSTRACT
The filamentous bacteriophage fd, codisplaying antigenic determinants and a single chain antibody fragment directed against the dendritic cell receptor DEC-205, is a promising vaccine candidate for its safety and its ability to elicit innate and adaptive immune response in absence of adjuvants. By using a system vaccinology approach based on RNA-Sequencing (RNA-Seq) analysis, we describe a relevant gene modulation in dendritic cells pulsed with anti-DEC-205 bacteriophages fd. RNA-Seq data analysis indicates that the bacteriophage fd virions are sensed as a pathogen by dendritic cells; they activate the danger receptors that trigger an innate immune response and thus confer a strong adjuvanticity that is needed to obtain a long-lasting adaptive immune response.
Subject(s)
Adaptive Immunity , Antigens, CD/metabolism , Bacteriophage M13/immunology , Bacteriophage M13/metabolism , Immunity, Innate , Immunomodulation , Lectins, C-Type/metabolism , Receptors, Cell Surface/metabolism , Animals , Bacteriophage M13/genetics , Cell Surface Display Techniques , Cluster Analysis , Dendritic Cells/immunology , Dendritic Cells/metabolism , Epitopes, T-Lymphocyte/immunology , Female , Gene Expression , Gene Expression Profiling , Lectins, C-Type/antagonists & inhibitors , Lymphocyte Activation/immunology , Mice , Mice, Transgenic , Minor Histocompatibility Antigens , Peptide Library , Receptors, Cell Surface/antagonists & inhibitors , Recombinant Fusion Proteins , Single-Chain Antibodies/genetics , Single-Chain Antibodies/metabolism , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , TranscriptomeABSTRACT
To date, several small molecule inhibitors and monoclonal-antibodies (like ICR-62) have been used to treat tumors over-expressing epidermal growth factor receptor (EGFR). However, the limitations associated with these conventional applications accentuate the necessity of alternative approaches. Mimotopes as compelling molecular tools could rationally be employed to circumvent these drawbacks. In the present study, an M13 phage displaying ICR-62 binding peptide mimotope is exploited as a vaccine candidate. It exhibited high affinity towards ICR62 and polyclonal anti-P-BSA antibodies. Following the mice immunization, phage-based mimotope vaccine induced humoral immunity. Elicited anti-EGFR mimotope antibodies were detected using ELISA method. Moreover, the phage vaccine was tested on the Lewis lung carcinoma mice model to investigate the prophylactic and therapeutic effects. The tumor volume was measured and recorded in different animal groups to evaluate the anti-tumor effects of the vaccine. Our data indicate that the reported phage-based mimotope could potentially elicit specific antibodies resulting in low titers of EGFR-specific antibodies and reduced tumor growth. However, in vivo experiments of prophylactic or therapeutic vaccination showed no specific advantage. Furthermore, phage-mimotope vaccine might be a promising approach in the field of cancer immunotherapy.
Subject(s)
Bacteriophage M13/immunology , Cancer Vaccines/immunology , Epitopes/immunology , ErbB Receptors/immunology , Neoplasms, Experimental/therapy , Vaccination , Animals , Bacteriophage M13/genetics , Cancer Vaccines/genetics , Cancer Vaccines/pharmacology , Cell Line, Tumor , Epitopes/genetics , Epitopes/pharmacology , ErbB Receptors/genetics , Female , Mice , Mice, Inbred BALB C , Neoplasms, Experimental/immunology , Neoplasms, Experimental/pathologyABSTRACT
The development of immunosensors for the detection of small molecules is of great interest because of their simplicity, high sensitivity and extended analytical range. Due to their size, small compounds cannot be simultaneously recognized by two antibodies impeding their detection by noncompetitive two-site immunoassays, which are superior to competitive ones in terms of sensitivity, kinetics, and working range. In this work, we combine the advantages of magneto-electrochemical immunosensors with the improved sensitivity and direct proportional signal of noncompetitive immunoassays to develop a new Phage Anti-Immunocomplex Electrochemical Immunosensor (PhAIEI) for the detection of the herbicide atrazine. The noncompetitive assay is based on the use of recombinant M13 phage particles bearing a peptide that specifically recognizes the immunocomplex of atrazine with an anti-atrazine monoclonal antibody. The PhAIEI performed with a limit of detection (LOD) of 0.2 pg mL(-1), which is 200-fold better than the LOD obtained using the same antibody in an optimized conventional competitive ELISA, with a large increase in working range. The developed PhAIEI was successfully used to assay undiluted river water samples with no pretreatment and excellent recoveries. Apart from the first demonstration of the benefits of integrating phage anti-immunocomplex particles into electrochemical immunosensors, the extremely low and environmentally relevant detection limits of atrazine attained with the PhAIEIS may have direct applicability to fast and sensitive detection of this herbicide in the environment.
Subject(s)
Antibodies, Viral/immunology , Atrazine/analysis , Bacteriophage M13/immunology , Biosensing Techniques/instrumentation , Conductometry/instrumentation , Immunoassay/instrumentation , Atrazine/immunology , Electrodes , Equipment Design , Equipment Failure Analysis , Herbicides/analysis , Herbicides/immunology , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
BACKGROUND: Filamentous phage display has become an ordinary tool to engineer antibody fragments. Several capsid proteins have been applied for displaying antibodies, of which gene III (p3) protein is used the most followed by experiments with gene IX (p9) protein. Despite the popularity, there are no library scale studies to objectively compare differences in the selection performance of the libraries, when displayed via different capsid proteins. RESULTS: In this study, an identical antibody repertoire was displayed as Fab fragments on p9, p3 and truncated p3 (p3Δ). In addition, the library clones were displayed as ScFv fragments on p3Δ and the Fab-p3 display valency was modulated by hyperphage and VCS-M13 superinfections. The selection performances of the libraries were followed in repeated parallel panning reactions against streptavidin (STR) and digoxigenin (DIG). Selection was successful with all display formats, but the enrichment of specific clones from Fab-p9 library was clearly less efficient than from the other libraries. The most diverse outputs were obtained from p3Δ display and the highest affinity anti-DIG antibodies from the ScFv repertoire. Unfortunately, the number of retrieved specific clones was too low for explicit analysis of the differences in the number of obtained unique clones from each library. However, severe reduction in sequence diversity was observed in p3-Fab libraries prior to panning, which in turn, materialized as a low number of unique specific clones. Oligovalent display by hyperphage resulted in a higher number of unique clones, but the same highest affinity anti-DIG Fab was recovered also by VCS-M13 superinfection. CONCLUSIONS: The compromised enrichment of the target-specific clones from the Fab repertoire as a fusion to p9 capsid protein in our experiments, the significant loss of functional diversity in Fab-p3 library after single phage packing cycle and the retrieval of higher affinity anti-digoxigenin clones as ScFv molecules than as Fab molecules from the same source repertoire indicate that the chosen display format may have a significant impact on the selection outcome. This study demonstrates that in addition to library content, also display related issues, should be taken into consideration when planning directed evolution experiments.
Subject(s)
Bacteriophage M13/metabolism , Capsid Proteins/metabolism , Cell Surface Display Techniques , Immunoglobulin Fab Fragments/metabolism , Peptide Library , Antibody Affinity , Bacteriophage M13/genetics , Bacteriophage M13/immunology , Capsid Proteins/genetics , Capsid Proteins/immunology , Digoxigenin/immunology , Digoxigenin/metabolism , Genetic Engineering , Immunoassay , Immunoglobulin Fab Fragments/genetics , Recombinant Fusion Proteins/metabolism , Streptavidin/immunology , Streptavidin/metabolismABSTRACT
BACKGROUND: Multiple myeloma is characterized by clonal expansion of B cells producing monoclonal immunoglobulins or fragments thereof, which can be detected in the serum and/or urine and are ideal target antigens for patient-specific immunotherapies. METHODS: Using phage particles as immunological carriers, we employed a novel chemically linked idiotype vaccine in a clinical phase I/II trial including 15 patients with advanced multiple myeloma. Vaccines composed of purified paraproteins linked to phage were manufactured successfully for each patient. Patients received six intradermal immunizations with phage idiotype vaccines in three different dose groups. RESULTS: Phage idiotype was well tolerated by all study participants. A subset of patients (80% in the middle dose group) displayed a clinical response indicated by decrease or stabilization of paraprotein levels. Patients exhibiting a clinical response to phage vaccines also raised idiotype-specific immunoglobulins. Induction of a cellular immune response was demonstrated by a cytotoxicity assay and delayed type hypersensitivity tests. CONCLUSION: We present a simple, time- and cost-efficient phage idiotype vaccination strategy, which represents a safe and feasible patient-specific therapy for patients with advanced multiple myeloma and produced promising anti-tumor activity in a subset of patients.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Bacteriophage M13/immunology , Cancer Vaccines/therapeutic use , Multiple Myeloma/therapy , Antibody Formation , Cancer Vaccines/administration & dosage , Cancer Vaccines/immunology , Humans , Multiple Myeloma/immunologyABSTRACT
Camelids have unique antibodies, namely HCAbs (VHH) or commercially named Nanobodies(®) (Nb) that are composed only of a heavy-chain homodimer. As libraries based on immunized camelids are time-consuming, costly and likely redundant for certain antigens, we describe the construction of a naïve camelid VHHs library from blood serum of non-immunized camelids with affinity in the subnanomolar range and suitable for standard immune applications. This approach is rapid and recovers VHH repertoire with the advantages of being more diverse, non-specific and devoid of subpopulations of specific antibodies, which allows the identification of binders for any potential antigen (or pathogen). RNAs from a number of camelids from Saudi Arabia were isolated and cDNAs of the diverse vhh gene were amplified; the resulting amplicons were cloned in the phage display pSEX81 vector. The size of the library was found to be within the required range (10(7)) suitable for subsequent applications in disease diagnosis and treatment. Two hundred clones were randomly selected and the inserted gene library was either estimated for redundancy or sequenced and aligned to the reference camelid vhh gene (acc. No. ADE99145). Results indicated complete non-specificity of this small library in which no single event of redundancy was detected. These results indicate the efficacy of following this approach in order to yield a large and diverse enough gene library to secure the presence of the required version encoding the required antibodies for any target antigen. This work is a first step towards the construction of phage display-based biosensors useful in disease (e.g., TB or tuberculosis) diagnosis and treatment.
Subject(s)
Antibodies, Bacterial/chemistry , Antibodies, Bacterial/immunology , Camelus/immunology , Peptide Library , Animals , Bacteria/immunology , Bacteriophage M13/immunology , Cell Line , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Escherichia coli/immunology , Immunoglobulin G/biosynthesis , Immunoglobulin G/immunology , Polymerase Chain Reaction , RNA/biosynthesis , RNA/isolation & purificationABSTRACT
The core antigen (HBcAg) of hepatitis B virus (HBV) is one of the markers for the identification of the viral infection. The main purpose of this study was to develop a TaqMan real-time detection assay based on the concept of phage display mediated immuno-PCR (PD-IPCR) for the detection of HBcAg. PD-IPCR combines the advantages of immuno-PCR (IPCR) and phage display technology. IPCR integrates the versatility of enzyme-linked immunosorbent assay (ELISA) with the sensitivity and signal generation power of PCR. Whereas, phage display technology exploits the physical association between the displayed peptide and the encoding DNA within the same phage particle. In this study, a constrained peptide displayed on the surface of an M13 recombinant bacteriophage that interacts tightly with HBcAg was applied as a diagnostic reagent in IPCR. The phage displayed peptide and its encoding DNA can be used to replace monoclonal antibody (mAb) and chemically bound DNA, respectively. This method is able to detect as low as 10ng of HBcAg with 10(8)pfu/ml of the recombinant phage which is about 10,000 times more sensitive than the phage-ELISA. The PD-IPCR provides an alternative means for the detection of HBcAg in human serum samples.
Subject(s)
Cell Surface Display Techniques , Hepatitis B Core Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Antibodies, Viral/genetics , Antibodies, Viral/immunology , Bacteriophage M13/genetics , Bacteriophage M13/immunology , Enzyme-Linked Immunosorbent Assay , Hepatitis B Core Antigens/genetics , Hepatitis B Core Antigens/immunology , Humans , Limit of Detection , Polymerase Chain Reaction , Sensitivity and SpecificityABSTRACT
Peptides displayed on the surface of filamentous bacteriophage fd are able to induce humoral as well as cell-mediated immune responses, which makes phage particles an attractive antigen delivery system to design new vaccines. The immune response induced by phage-displayed peptides can be enhanced by targeting phage particles to the professional antigen presenting cells, utilizing a single-chain antibody fragment that binds dendritic cell receptor DEC-205. Here, we review recent advances in the use of filamentous phage fd as a platform for peptide vaccines, with a special focus on the use of phage fd as an antigen delivery platform for peptide vaccines in Alzheimer's Disease and cancer.
Subject(s)
Bacteriophage M13/immunology , Capsid Proteins/immunology , Cell Surface Display Techniques/methods , Drug Carriers/administration & dosage , Vaccines, Subunit/immunology , Amyloid beta-Peptides/immunology , Animals , Capsid/immunology , Capsid/metabolism , Capsid Proteins/metabolism , Dendritic Cells/immunology , Mice , Peptide Library , T-Lymphocytes, Cytotoxic/immunology , Vaccination/methods , Vaccines, Subunit/administration & dosageABSTRACT
We demonstrate the de novo fabrication of a biosensor, based upon virus-containing poly(3,4-ethylene-dioxythiophene) (PEDOT) nanowires, that detects prostate-specific membrane antigen (PSMA). This development process occurs in three phases: (1) isolation of a M13 virus with a displayed polypeptide receptor, from a library of ≈10(11) phage-displayed peptides, which binds PSMA with high affinity and selectivity, (2) microfabrication of PEDOT nanowires that entrain these virus particles using the lithographically patterned nanowire electrodeposition (LPNE) method, and (3) electrical detection of the PSMA in high ionic strength (150 mM salt) media, including synthetic urine, using an array of virus-PEDOT nanowires with the electrical resistance of these nanowires for transduction. The electrical resistance of an array of these nanowires increases linearly with the PSMA concentration from 20 to 120 nM in high ionic strength phosphate-buffered fluoride (PBF) buffer, yielding a limit of detection (LOD) for PSMA of 56 nM.
Subject(s)
Antigens, Surface/analysis , Antigens, Surface/immunology , Bacteriophage M13/immunology , Biosensing Techniques/instrumentation , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Glutamate Carboxypeptidase II/analysis , Glutamate Carboxypeptidase II/immunology , Nanowires/chemistry , Polymers/chemistry , Prostatic Neoplasms/diagnosis , Amino Acid Sequence , Bacteriophage M13/isolation & purification , Equipment Design , Humans , Limit of Detection , Male , Peptide Library , Peptides/chemistry , Peptides/immunology , Prostatic Neoplasms/immunologyABSTRACT
A method for generation of highly specific miniantibodies within the phage particle has been developed, and used to produce antibodies against Staphylococcus enterotoxin type C1. Under successive panning of the non-immune phage miniantibody (scFv) library with enterotoxins SE (types A, B, C1, D, E, G, and I) adsorbed on the plate surface, we generated 11 individual phage clones to Staphylococcus enterotoxin type C1. Five of them interacted specifically only with SEC1 and had no cross-reactions with the other enterotoxins.
Subject(s)
Antibody Specificity , Bacteriophage M13/immunology , Enterotoxins/immunology , Peptide Library , Single-Chain Antibodies/immunology , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/immunology , Bacteriophage M13/genetics , Cloning, Molecular , Enterotoxins/classification , Enzyme-Linked Immunosorbent Assay , Staphylococcus/immunology , Staphylococcus/metabolismABSTRACT
Hepatitis B is a major public health problem worldwide, which may lead to chronic liver diseases such as cirrhosis and hepatocellular carcinoma. The hepatitis B core antigen (HBcAg) is one of the major viral proteins, which forms the inner core of hepatitis B virus (HBV) particles. In this study, filamentous bacteriophage M13 was genetically modified to display the polypeptides of HBcAg in order to develop an alternative carrier system. HBcAg gene was inserted into the minor coat protein (pIII) gene of M13, and HBcAg was expressed on the phage surface as a whole protein. Antigenicity and immunogenicity of HBcAg were tested by immunizing BALB/c mice three times with HBcAg-displaying recombinant phages. After successful immunization, one of the mice with high antibody titer to HBcAg was selected for fusion, and four monoclonal antibodies specific for HBcAg were developed. This result showed that HBcAg-displaying recombinant bacteriophages are immunogenic and can potentially be used for the development of monoclonal antibodies.
Subject(s)
Bacteriophage M13/immunology , Gene Expression , Hepatitis B Core Antigens/genetics , Hepatitis B Core Antigens/immunology , Animals , Antibodies, Viral/immunology , Bacteriophage M13/genetics , Hepatitis B/immunology , Hepatitis B/virology , Humans , Immunization , Mice , Mice, Inbred BALB CABSTRACT
In Alzheimer's disease (AD), amyloid-ß (Aß) peptides accumulate in the brain in different forms, including fibrils and oligomers. Recently, we established three distinct conformation-dependent human single-chain Fv (scFv) antibodies, including B6 scFv, which bound to Aß42 fibril but not to soluble-form Aß, inhibiting Aß42 fibril formation. In this study, we determined the mimotopes of these antibodies and found a common mimotope sequence, B6-C15, using the Ph.D.-C7C phage library. The B6-C15 showed weak homology to the C-terminus of Aß42 containing GXXXG dimerization motifs. We synthesized the peptide of B6-C15 fused with biotinylated TAT at the N-terminus (TAT-B6-C15) and characterized its biochemical features on an Aß42-fibrillation reaction in vitro. We demonstrated that, first, TAT-B6-C15 inhibited Aß42 fibril formation; secondly, TAT-B6-C15 bound to prefibril Aß42 oligomers but not to monomers, trimers, tetramers, fibrils, or ultrasonicated fragments; thirdly, TAT-B6-C15 inhibited Aß42-induced cytotoxicity against human SH-SY5Y neuroblastoma cells; and, fourthly, when mice were administered B6-C15-phages dissolved in phosphate-buffered saline, the anti-Aß42 conformer IgG antibody response was induced. These results suggested that the B6-C15 peptide might provide unique opportunities to analyze the Aß42 fibrillation pathway and develop a vaccine vehicle for Alzheimer's disease.